Discovery Process for Antibody-Based Therapeutics

  • Heather H. Shih


Antibody-based therapeutics have entered the center stage of drug discovery as a result of a major shift in focus of many pharmaceutical companies from small molecules to a broader portfolio containing both protein and chemical therapeutic agents. The field is benefiting from both an increased understanding of the mechanistic basis of antibody-derived therapeutics and the development of sophisticated technologies to derive safe and targeted biotherapeutics. This chapter provides a general overview of the discovery process relevant for generation of antibody-based therapeutics. The discussion elaborates on target selection and validation, screening preparation, lead identification and optimization, as well as clinical candidate selection. In addition, an overview of immunogenicity, a unique challenge for protein-based therapeutics, is provided. A case study is also included to illustrate the discovery process for bapineuzumab, a humanized anti-amyloid beta (Aβ) monoclonal antibody, currently in Phase III clinical trials for the treatment of Alzheimer’s disease.


Therapeutic Antibody Drug Discovery Process Lead Molecule Therapeutic Candidate Clinical Candidate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ (2006) Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55:1451–1458PubMedCrossRefGoogle Scholar
  2. Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Dev 10:219–227Google Scholar
  3. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K et al (2003) Epitope and isotype specificities of antibodies to beta—amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 100:2023–2028PubMedCrossRefGoogle Scholar
  4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919PubMedCrossRefGoogle Scholar
  5. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B (2007) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27:269–274PubMedCrossRefGoogle Scholar
  6. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175–193PubMedCrossRefGoogle Scholar
  7. Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B (2007) Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8:761–773PubMedCrossRefGoogle Scholar
  8. Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24:1431–1440PubMedCrossRefGoogle Scholar
  9. Daugherty AL, Mrsny RJ (2010) Formulation and delivery issues for monoclonal antibody therapeutics. Biotechnology: Pharmaceutical aspects (Current trends in monoclonal antibody development and manufacturing), vol 11. Springer, New York, pp 103–129Google Scholar
  10. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood 112:3303–3311PubMedCrossRefGoogle Scholar
  11. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:8850–8855PubMedCrossRefGoogle Scholar
  12. Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104–111PubMedCrossRefGoogle Scholar
  13. Easthope S, Jarvis B (2001) Omalizumab. Drugs 61:253–260 discussion 261PubMedCrossRefGoogle Scholar
  14. Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, Canonico PL (2007) Biosimilar drugs: concerns and opportunities. Biodrugs 21:351–356PubMedCrossRefGoogle Scholar
  15. Gilles JG, Vanzieleghem B, Saint-Remy JM (2000) Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes. Semin Thromb Hemost 26:151–155PubMedCrossRefGoogle Scholar
  16. Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714–727PubMedCrossRefGoogle Scholar
  17. Jahn EM, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic proteins—regulatory considerations. N Biotechnol 25:280–286PubMedCrossRefGoogle Scholar
  18. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2010) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347–356PubMedCrossRefGoogle Scholar
  19. Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10:1121–1130PubMedCrossRefGoogle Scholar
  20. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  21. Lichtlen P, Mohajeri MH (2008) Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104:859–874PubMedCrossRefGoogle Scholar
  22. Maggi E, Vultaggio A, Matucci A (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7:55–63PubMedCrossRefGoogle Scholar
  23. Morgan D (2011) Immunotherapy for Alzheimer’s disease. J Int Med 269:54–63CrossRefGoogle Scholar
  24. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774PubMedCrossRefGoogle Scholar
  25. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, Handa M, Horwitz AH, Roell MK, Haak-Frendscho M, Masat L (2011) XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs 3:49–60PubMedCrossRefGoogle Scholar
  26. Pan W, Solomon B, Maness LM, Kastin AJ (2002) Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide. Exp Biol Med (Maywood) 227:609–615Google Scholar
  27. Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76–99PubMedCrossRefGoogle Scholar
  28. Schellekens H (2005) Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 18:473–480PubMedCrossRefGoogle Scholar
  29. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177PubMedCrossRefGoogle Scholar
  30. Selkoe DJ (2001) Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3:75–80PubMedGoogle Scholar
  31. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33:67–73PubMedCrossRefGoogle Scholar
  32. Stebbings R, Poole S, Thorpe R (2009) Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20:673–677PubMedCrossRefGoogle Scholar
  33. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF 3rd (2000) Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 275:36073–36078Google Scholar
  34. Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20:685–691PubMedCrossRefGoogle Scholar
  35. Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L (2009) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14:298–305PubMedCrossRefGoogle Scholar
  36. Tsurushita N, Park M, Pakabunto K, Ong K, Avdalovic A, Fu H, Jia A, Vasquez M, Kumar S (2004) Humanization of a chicken anti-IL-12 monoclonal antibody. J Immunol Methods 295:9–19PubMedCrossRefGoogle Scholar
  37. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284:3273–3284PubMedCrossRefGoogle Scholar
  38. Wang W, Singh S, Zeng DL, King K, Nema S (2007) Antibody structure, instability, and formulation. J Pharm Sci 96:1–26PubMedCrossRefGoogle Scholar
  39. Wong D, Joussen AM (2010) The safety of using anti-VEGF: is there strength in numbers? Graefes Arch Clin Exp Ophthalmol 249:161–162CrossRefGoogle Scholar
  40. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA (2007) Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 368:652–665PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.External Research SolutionsPfizerCambridgeUSA

Personalised recommendations